Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab

NCT03078855 is registered in ClinicalTrials.gov with Jonathan Friedberg as lead sponsor.

NCT NCT03078855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03078855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab
Lead sponsor
Jonathan Friedberg
Phase
Phase 3
Overall status
Completed
Start date
September 7, 2017
Completion date
July 2, 2024
Enrollment
211 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

follicular lymphoma, marginal zone lymphoma, mucosal-associated lymphoid tissue lymphoma, small lymphocytic lymphoma